Answers are grounded in this paper and cite their sources.
To assess the clinical benefit and actionability of molecular targets for genome targeted cancer drugs recommended for clinical practice by the National Comprehensive Cancer Network (NCCN).
No takes yet. Share an insight, caveat, or question.
Tibau et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: